Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Morgan Stanley Warns Against Overestimating EV Demand Boost from Rising Oil Prices 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
South Korea Central Bank Signals Cautious Policy Amid Inflation and Middle East Tensions 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
China vs. NASA: The New Moon Race and What's at Stake by 2030 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Oil Prices Surge Amid U.S.-Iran Tensions and Strait of Hormuz Disruptions 
A South Korean research team has developed a strip-type urine test that successfully diagnoses prostate and pancreatic cancer on-site by amplifying the optical signal of the metabolome in urine.
The joint research team is from the Korea Institute of Materials Science, Pohang University of Science and Technology, and Kyung Hee University
The surface-enhanced Raman scattering sensor that they developed can amplify the optical signal of the metabolome in urine by more than 1 billion times by forming a coral reef-shaped plasmonic nanomaterial on top of porous paper material.
A light irradiation after a 10-microliter urine droplet amplified signal of cancer metabolome on the sensor’s surface without the need to go through a separate analysis process,.
The application of an artificial intelligence-based analytical method for the spectrum signal generated through the irradiation of light into the urine can identify people with prostate cancer and pancreatic cancer with an accuracy of up to 99 percent.
